New research from the 2026 American Society of Clinical Oncology (ASCO) annual meeting, and presented on Cure Today, highlights an encouraging new treatment on the horizon for advanced non-small cell…
Merck and Gilead Sciences reported contrasting late-stage outcomes on Monday, pairing a promising advance in HIV treatment with the discontinuation of a high-profile lung cancer trial after underwhelming survival results.…
As reported on FiercePharma, China-based biotech Dizal Pharmaceutical has reported a pivotal phase 3 success for its oral EGFR inhibitor Zegfrovy (sunvozertinib), marking a potential shift in first-line treatment for…
As reported on Business Wire, ImmunityBio has released new clinical findings suggesting that its interleukin‑15 superagonist, ANKTIVA® (nogapendekin alfa inbakicept), may help restore immune function and improve survival outcomes in…
As reported on PharmaBiz, AstraZeneca’s phase III LATIFY trial has fallen short of its primary objective, with the combination of the ATR inhibitor ceralasertib and the PD‑L1 inhibitor Imfinzi (durvalumab)…
Immuneering’s midstage pancreatic deep cyclic MEK protein inhibitor, (DCI), almost doubled the standard overall survival. It is a deep cycle inhibitor that targets key pathways in a pulsed manner. Results…
A new study has found that corticosteroids, commonly used to manage symptoms in lung cancer patients, may reduce the effectiveness of immunotherapy treatments. The research, highlighted by News-Medical.net, sheds light…
My name is May, and I was diagnosed with lung cancer in May of 2022. I was 37 years old — a wife, a mother to a toddler, and someone…
Let’s start at the beginning of my long journey. My name is Laura, and around fifteen years ago, I was diagnosed with type-2 diabetes and prescribed medication to control it.…
The month of November is recognized around the world as Lung Cancer Awareness Month, a time to advocate and spread awareness about lung cancer. This form of cancer is not…
The 2023 World Conference on Lung Cancer took place from September 9-12 this year. During the conference, stakeholders came together to discuss novel research, emerging trends, and other needs…
Advancing patient outcomes hinges on the development of targeted treatments, particularly in conditions with grim prognoses such as small cell lung cancer (SCLC), which typically has a life expectancy…
Roche has recently been granted priority review by the FDA, who has also accepted their supplemental biologics license application for atezolizumab. Atezolizumab is intended for the treatment of non-small cell…
According to a story from us.acrofan.com, the biopharmaceutical company AstraZeneca recently announced the release of positive results for a clinical trial testing the company's drug durvalumab (marketed as IMFINZI) in…
According to a publication from Augusta University, a recent study lung cancer patients receiving chemotherapy provided a possible explanation for some cancers' ability to resist treatment. The research, conducted by…
Pattern.Org Pattern.org was created by the Rare Cancer Research Foundation, a nonprofit dedicated to improving the lives of rare cancer patients by accelerating research. Pattern.org specifically, is a branch of…
NSCLC Non-small cell lung cancer or NSCLC is the most common kind of lung cancer diagnosis. It affects over 2 million people and of those, there's a small group who…
For some fortunate individuals, cancer is kind of a foreign concept. They obviously know what it is- they hear cancer stories in passing, they may have donated to a charity…
According to a report by American Health and Drug Benefits, a new blood test may change cancer screening. The new test would allow for earlier detection than current techniques. Supporting…
In an Article from AsiaOne.com, we meet John Ryan, retired nuclear reactor specialist who worked for the military when he was diagnosed with lung cancer. Now in remission he might…
A recent study published in the Lancet has investigated the effects of starting chemotherapy on patient survival, according to the UK Government website. It was found that many factors can…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
